OncoMatch/Clinical Trials/NCT07092696
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
Is NCT07092696 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Toripalimab for cervical cancer.
Treatment: Toripalimab — To explore the efficacy and tolerability of a platinum-based regimen combined with the PD-1 antibody toripalimab administered prior to concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: PD-1/PD-L1/PD-L2/CTLA-4/CD137 inhibitor or other T-cell checkpoint modulator (ipilimumab)
Prior therapy with any agent targeting PD-1, PD-L1, PD-L2, CD137, CTLA-4 (e.g., ipilimumab), or any other antibody or drug that modulates T-cell co-stimulation or checkpoint pathways.
Lab requirements
Blood counts
WBC ≥ 4 × 10⁹/L, ANC ≥ 1.5 × 10⁹/L, platelets ≥ 100 × 10⁹/L, Hb ≥ 90 g/L
Kidney function
BUN ≤ 1.5 × ULN, creatinine ≤ 1.5 × ULN
Liver function
TBIL ≤ 1.5 × ULN, ALT/AST ≤ 2.5 × ULN
Cardiac function
No clinically significant cardiac arrhythmias, myocardial ischemia, severe conduction block, heart failure, or severe valvular disease.
Laboratory values: WBC > 4 × 10⁹/L; platelets > 100 × 10⁹/L. Inadequate hematologic or organ function: WBC < 4.0 × 10⁹/L, ANC < 1.5 × 10⁹/L, platelets < 100 × 10⁹/L, Hb < 90 g/L; TBIL > 1.5 × ULN, ALT/AST > 2.5 × ULN, BUN > 1.5 × ULN, creatinine > 1.5 × ULN. Clinically significant cardiac arrhythmias, myocardial ischemia, severe conduction block, heart failure, or severe valvular disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07092696 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages